ARVN Q3 2024 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$102M+196.0% YoY

Gross Profit

$102M100.0% margin

Operating Income

-$60M-58.9% margin

Net Income

-$49M-48.0% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

+33.9%

Cash Flow

Operating Cash Flow

-$128M

Free Cash Flow

-$129M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$581M

Stockholders' Equity

$586M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$102M	$35M	+196.0%
Gross Profit	$102M	$33M	+211.2%
Operating Income	-$60M	-$74M	+18.4%
Net Income	-$49M	-$64M	+23.1%

Revenue Segments

License

$130M100%